Ilumya™ (tildrakizumab-asmn) – New drug approval
March 21, 2018 - Sun Pharma announced the FDA approval of Ilumya (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Download PDF
